merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Eli Lilly positions its vials as a safer option than compounded drugs, which are subject to far less oversight than traditionally approved medications</answer>

<question_number>2</question_number>
<answer>Like compounded drugs prescribed by online startups, Zepbound vials can be delivered right to patients' doors through LillyDirect</answer>

<question_number>3</question_number>
<answer>Compounded drugs are subject to far less oversight than traditionally approved medications, and health officials have repeatedly warned against taking compounded weight-loss drugs</answer>

<question_number>4</question_number>
<answer>Dr. Timothy Mackey suggests this signals to the compounded drug space: "We will get this market share back from you, even if it means lower pricing"</answer>

<question_number>5</question_number>
<answer>Compounding pharmacies can make copycat versions of any medication the FDA lists as "in shortage," and when tirzepatide is off the shortage list, "there should be no space for mass compounders"</answer>

<question_number>6</question_number>
<answer>The company can offer "transparent pricing" for the vials because it can sell the drug directly, "removing third-party supply chain entities"</answer>

<question_number>7</question_number>
<answer>N/A</answer>

<question_number>8</question_number>
<answer>N/A</answer>

<question_number>9</question_number>
<answer>Being listed as "in shortage" by the FDA</answer>

<question_number>10</question_number>
<answer>Lower pricing</answer>